2020
DOI: 10.15825/1995-1191-2019-4-54-66
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of the effectiveness of combined treatment of coronary heart disease – coronary artery bypass grafting, transplantation of autologous bone marrow mononuclear cells: a randomized, double-blind, placebo-controlled study

Abstract: Введение. Несмотря на несомненные успехи в лечении пациентов с ишемической болезнью сердца (ИБС), пока не удается добиться существенного снижения смертности при данном заболевании. Учитывая это, в настоящий момент повсеместно ведутся работы в отношении исследования новых методик с целью увеличить эффективность уже существующих стандартов. Одной из таких перспективных методик является клеточная/регенеративная терапия аутологичными мононуклеарами костного мозга (АМНКМ). Однако несмотря на то что АМНКМ исследуютс… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 23 publications
0
3
0
Order By: Relevance
“…This ensures long-term perfusion control and stability on that ischemic and peri-ischemic area [ 3 , 27 , 31 ]. In the end, this leads to a long-term and broader LV reverse remodeling [ 3 , 22 , 27 ]. These three mechanisms together result in the improvement of cardiac function.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…This ensures long-term perfusion control and stability on that ischemic and peri-ischemic area [ 3 , 27 , 31 ]. In the end, this leads to a long-term and broader LV reverse remodeling [ 3 , 22 , 27 ]. These three mechanisms together result in the improvement of cardiac function.…”
Section: Discussionmentioning
confidence: 99%
“…This improvement in the responders will continue over time in a long-term period, while not for non-responders [ 33 ]. Low LV volume and diameter levels contributed to the responder group, as these levels are believed to be determined by the extent of viable myocardial cells [ 22 , 32 , 33 ]. A previous study showed that LVESVI 70 mL/m 2 was the cut-off point for determining whether a patient would respond to stem cell-based treatment or not [ 33 ].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation